COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00375557
Recruitment Status : Withdrawn
First Posted : September 13, 2006
Last Update Posted : May 27, 2015
Information provided by (Responsible Party):
Muhammad Aslamm, University of Cincinnati

Brief Summary:
The primary aim is to determine whether Divalproex ER or one of the atypical antipsychotics is more effective improving dementia related behavioral symptoms in patients with dementia, and evaluate the impact of such improvements on other clinical domains, such as quality of life, functional status.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Dementia Behavioral Symptoms Drug: Divalproex ER Drug: Quetiapine Phase 4

Detailed Description:
This clinical trial will be open label, flexible dose study of Divalproex ER vs Quetiapine for 6 weeks. Patients will be randomized to Divalproex ER vs Quetiapine outpatient / inpatient. The schedule of visits will include a screening, a baseline and 3 treatment visits / assessment. The End of Study/Early Termination visit will conclude the Trial. The safety follow-up visit will be scheduled only for the patients with unresolved Adverse Events detected prior or at the End of Study/Early Termination visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Randomized, Flexible Dose, 6-week Clinical Trial of the Safety and Efficacy of Divalproex ER vs Quetiapine in the Treatment of Behavioral Symptoms in the Elderly With Moderate to Severe Alzheimer's Dementia
Study Start Date : October 2006
Actual Study Completion Date : September 2007

Arm Intervention/treatment
Active Comparator: 1
Drug: Quetiapine
Quetiapine will be initiated in 25 mg/day, with a variable dosing frequency (QD-TID). The daily dose of Quetiapine will be titrated up by 25-50 mg each day based on patients' response and tolerability, not to exceed a maximum of 750 mg/day.
Other Name: Seroquel

Active Comparator: 2
Divalproex ER
Drug: Divalproex ER
Divalproex ER will be initiated on 250 mg/day, dosed once daily. The daily dose of Divalproex ER will be titrated up 250 mg each day based on patients' response and tolerability, not to exceed a maximum of 2000 mg/day.
Other Name: Depakote ER

Primary Outcome Measures :
  1. The change from the Baseline to the End of the Study/Early Termination visit in the CMAI & Quality of life scale scores. [ Time Frame: 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Patients, men and women =/> 55 years of age.
  2. Inpatient / Outpatients with diagnosis of Moderate to Severe probable Alzheimer's dementia as determined by the Structured Clinical Interview for DSM-IV.
  3. Patients with a Mini Mental Status Examination scores between 3-15 at screening.
  4. Patients and Care Giver/ Legal representative or Guardian who are able to comprehend and satisfactorily comply with protocol requirements.
  5. Patient, Care Giver/ Legal representative or Guardian who signed the written informed consent given prior to entering any study procedure.
  6. Patients who have been at least three month ongoing stable dose of cholinesterase enzyme inhibitors or memantine.

Exclusion Criteria:

  1. Patients with a concurrent DSM-IV Axis I diagnosis in any of the following categories:

    1.1. Delirium, Amnestic and other Cognitive disorders 1.2. Lifetime Schizophrenia and other Psychotic Disorders 1.3. Lifetime Bipolar I Disorder 1.4. Bipolar 11 Disorder with an episode of hypomania within the last year 1.5. Alcohol or Substance Dependence or Abuse (excluding nicotine) in one month prior to the Screening Visit

  2. Patients with a history of intolerance or hypersensitivity to Divalproex ER & Quetiapine.
  3. Patients who have a history of seizures.
  4. Patients who based on history or mental status examination have a significant risk of committing suicide.
  5. Patients who are homicidal or violent and who are in the Investigator's opinion in significant imminent risk of hurting others.
  6. Patients who have been treated with depot-neuroleptic within 3 months prior to the Baseline Visit.
  7. Patients with a positive urine drug screen, unless proven to be prescribed for a short-term course of treatment. In these situations a urine drug screen must be repeated at least 7 days after the last dose of the prescription medication containing narcotics.
  8. Patients who have participated in any clinical trial within one month prior to the Screening Visit, or in a clinical trial involving a psychotropic medication within the 3 months prior to the Screening Visit.
  9. Patients who have a medical condition that, in the Investigator's opinion, would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the course of the trial.
  10. Patients with any current malignancy, or any clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal or neurological disease (including any form of epilepsy). If there is a history of such disease but the condition has been stable for at least the past year and is judged by the investigator not to interfere with the patient's participation in the study, the patient may be included.
  11. Patients with systolic blood pressure greater than 180 mm Hg or less than 90 mm Hg or diastolic blood pressure greater than 105 mm Hg or less than 50 mm Hg at the Screening visit.
  12. Patients who test positive for Hepatitis B surface antigen or Hepatitis C antibody.
  13. Patients whose laboratory values at the Screening visit will be 1.5 times greater than ULN.
  14. Patients requiring concomitant treatment with any psychotropic drug (except zolpidem for sleep no more than 3x/week prn).
  15. Patients who require concomitant therapy with any prohibited prescription.
  16. Patients who are unable to speak, read, and understand English or are judged by the investigator to be unable or unlikely to follow the study protocol and complete all scheduled visits.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00375557

Layout table for location information
United States, Ohio
Cincinnati VA Hospital
Cincinnati, Ohio, United States, 45220
Sponsors and Collaborators
University of Cincinnati
Layout table for investigator information
Principal Investigator: Muhammad Aslam, MD University of Cincinnati/ VA Medical Center
Layout table for additonal information
Responsible Party: Muhammad Aslamm, Associate Professor, University of Cincinnati Identifier: NCT00375557    
Other Study ID Numbers: 06-08-25-06
First Posted: September 13, 2006    Key Record Dates
Last Update Posted: May 27, 2015
Last Verified: May 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Behavioral Symptoms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Valproic Acid
Quetiapine Fumarate
Antidepressive Agents
Psychotropic Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
GABA Agents
Neurotransmitter Agents
Antimanic Agents